Revisiting the two-mass model of the vocal folds

Realistic mathematical modeling of voice production has been recently boosted by applications to different fields like bioprosthetics, quality speech synthesis and pathological diagnosis. In this work, we revisit a two-mass model of the vocal folds that includes accurate fluid mechanics for the air passage through the folds and nonlinear properties of the tissue. We present the bifurcation diagram for such a system, focusing on the dynamical properties of two regimes of interest: the onset of oscillations and the normal phonation regime. We also show theoretical support to the nonlinear nature of the elastic properties of the folds tissue by comparing theoretical isofrequency curves with reported experimental data.Comment: 7 pages, 5 figure

Nonlinear model predicts diverse respiratory patterns of birdsong

Journal ArticleA central aspect of the motor control of birdsong production is the capacity to generate diverse respiratory rhythms, which determine the coarse temporal pattern of song. The neural mechanisms that underlie this diversity of respiratory gestures and the resulting acoustic syllables are largely unknown. We show that the respiratory patterns of the highly complex and variable temporal organization of song in the canary (Serinus canaria) can be generated as solutions of a simple model describing the integration between song control and respiratory centers. This example suggests that subharmonic behavior can play an important role in providing a complex variety of responses with minimal neural substrate

Discrete Anatomical Coordinates for Speech Production and Synthesis

The sounds of all languages are described by a finite set of symbols, which are extracted from the continuum of sounds produced by the vocal organ. How the discrete phonemic identity is encoded in the continuous movements producing speech remains an open question for the experimental phonology. In this work, this question is assessed by using Hall-effect transducers and magnets—mounted on the tongue, lips, and jaw—to track the kinematics of the oral tract during the vocalization of vowel-consonant-vowel structures. Using a threshold strategy, the time traces of the transducers were converted into discrete motor coordinates unambiguously associated with the vocalized phonemes. Furthermore, the signals of the transducers combined with the discretization strategy were used to drive a low-dimensional vocal model capable of synthesizing intelligible speech. The current work not only assesses a relevant inquiry of the biology of language, but also demonstrates the performance of the experimental technique to monitor the displacement of the main articulators of the vocal tract while speaking. This novel electronic device represents an economic and portable option to the standard systems used to study the vocal tract movements

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p<0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (<1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (<1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline